NASDAQ : AVLN
Avalyn Pharma Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 25.95 USD (Nov 2, 2026, 2:15 PM EST) · Market cap 1.15B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 18.97M | 14.68M | 9.96M |
| Research & Development | 91.03M | 76.61M | 45.76M |
| Operating Expenses | 110.00M | 91.29M | 55.72M |
| Operating Income | -110.00M | -91.29M | -55.72M |
| Interest & Investment Income | 7.12M | 6.18M | 7.44M |
| Other Non Operating Income (Expenses) | -69.00K | -89.00K | -17.00K |
| EBT Excluding Unusual Items | -103.31M | -85.20M | -48.30M |
| Gain (Loss) on Sale of Assets | -45.00K | ||
| Legal Settlements | -1.40M | ||
| Pretax Income | -103.31M | -85.20M | -49.74M |
| Net Income | -103.31M | -85.20M | -49.74M |
| Net Income to Common | -103.31M | -85.20M | -49.74M |
| Shares Outstanding (Basic) | 8.37M | 971.06K | 270.14K |
| Shares Outstanding (Diluted) | 8.37M | 971.06K | 270.14K |
| EPS (Basic) | -12.34 | -87.74 | -184.14 |
| EPS (Diluted) | -12.34 | -87.74 | -184.14 |
| Free Cash Flow | -98.40M | -81.83M | -48.46M |
| Free Cash Flow Per Share | -11.75 | -84.27 | -179.40 |
| EBITDA | -109.80M | -91.25M | -55.69M |
| D&A For EBITDA | 196.00K | 42.00K | 29.00K |
| EBIT | -110.00M | -91.29M | -55.72M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 264.20M | 52.31M | 23.95M |
| Short-Term Investments | 88.23M | 86.09M | 86.68M |
| Cash & Short-Term Investments | 352.43M | 138.41M | 110.63M |
| Other Receivables | 1.67M | 537.00K | 591.00K |
| Receivables | 1.67M | 537.00K | 591.00K |
| Prepaid Expenses | 1.61M | 706.00K | 308.00K |
| Other Current Assets | 2.28M | 3.91M | 2.86M |
| Total Current Assets | 357.99M | 143.56M | 114.39M |
| Property, Plant & Equipment | 3.35M | 2.32M | 94.00K |
| Long-Term Investments | 61.10M | 7.49M | |
| Other Long-Term Assets | 3.01M | 3.00M | 2.55M |
| Total Assets | 425.45M | 148.88M | 124.52M |
| Accounts Payable | 2.65M | 3.76M | 2.28M |
| Accrued Expenses | 7.34M | 9.89M | 6.47M |
| Current Portion of Leases | 816.00K | 444.00K | |
| Total Current Liabilities | 10.81M | 14.09M | 8.74M |
| Long-Term Leases | 1.49M | 1.23M | |
| Total Liabilities | 27.10M | 15.32M | 8.74M |
| Common Stock | 67.00K | 24.00K | 5.00K |
| Additional Paid-In Capital | 719.54M | 26.55M | 5.43M |
| Retained Earnings | -321.17M | -265.36M | -180.16M |
| Comprehensive Income & Other | -95.00K | 134.00K | 202.00K |
| Total Common Equity | 398.35M | -238.66M | -174.52M |
| Shareholders' Equity | 398.35M | 133.56M | 115.78M |
| Total Liabilities & Equity | 425.45M | 148.88M | 124.52M |
| Total Debt | 17.11M | 1.67M | |
| Net Cash (Debt) | 396.42M | 136.74M | 118.12M |
| Net Cash Per Share | 47.34 | 140.82 | 437.25 |
| Filing Date Shares Outstanding | 44.33M | 1.23M | 276.82K |
| Total Common Shares Outstanding | 44.33M | 1.23M | 276.82K |
| Working Capital | 347.18M | 129.47M | 105.64M |
| Book Value Per Share | 8.99 | -194.47 | -630.46 |
| Tangible Book Value | 398.35M | -238.66M | -174.52M |
| Tangible Book Value Per Share | 8.99 | -194.47 | -630.46 |
| Machinery | 436.00K | 164.00K | 106.00K |
| Construction In Progress | 682.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -103.31M | -85.20M | -49.74M |
| Depreciation & Amortization | 196.00K | 42.00K | 79.00K |
| Loss (Gain) From Sale of Assets | 45.00K | ||
| Loss (Gain) From Sale of Investments | -1.74M | -2.35M | -2.58M |
| Stock-Based Compensation | 5.59M | 3.27M | 2.47M |
| Other Operating Activities | 367.00K | 146.00K | |
| Change in Accounts Payable | 1.56M | 1.40M | 231.00K |
| Change in Other Net Operating Assets | -159.00K | 1.22M | 1.13M |
| Operating Cash Flow | -97.48M | -81.48M | -48.37M |
| Capital Expenditures | -923.00K | -344.00K | -95.00K |
| Investment in Securities | -40.14M | 10.40M | -91.38M |
| Investing Cash Flow | -41.06M | 10.06M | -91.47M |
| Issuance of Common Stock | 320.90M | 18.00K | 51.00K |
| Other Financing Activities | -4.94M | -594.00K | |
| Financing Cash Flow | 341.44M | 99.79M | 89.00K |
| Net Cash Flow | 202.90M | 28.36M | -139.75M |
| Free Cash Flow | -98.40M | -81.83M | -48.46M |
| Free Cash Flow Per Share | -11.75 | -84.27 | -179.40 |
| Levered Free Cash Flow | -50.58M | ||
| Unlevered Free Cash Flow | -50.58M | ||
| Change in Working Capital | 1.41M | 2.61M | 1.36M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.15B | ||
| Enterprise Value | 750.03M | ||
| Debt / Equity Ratio | 0.04 | 0.01 | |
| Net Debt / Equity Ratio | -0.99 | -1.02 | -1.02 |
| Net Debt / EBITDA Ratio | 3.61 | 1.50 | 2.12 |
| Net Debt / FCF Ratio | 4.03 | 1.67 | 2.44 |
| Quick Ratio | 32.76 | 9.86 | 12.72 |
| Current Ratio | 33.12 | 10.19 | 13.08 |
| Return on Equity (ROE) | -68.34% | ||
| Return on Assets (ROA) | -41.74% | ||
| Return on Capital Employed (ROCE) | -26.50% | -67.70% | -48.10% |
| Buyback Yield / Dilution | -259.46% |